KR930703236A - 리그난 유사체. 이의 제조방법 및 이를 함유한 항지혈증제 - Google Patents

리그난 유사체. 이의 제조방법 및 이를 함유한 항지혈증제

Info

Publication number
KR930703236A
KR930703236A KR1019930701814A KR930701814A KR930703236A KR 930703236 A KR930703236 A KR 930703236A KR 1019930701814 A KR1019930701814 A KR 1019930701814A KR 930701814 A KR930701814 A KR 930701814A KR 930703236 A KR930703236 A KR 930703236A
Authority
KR
South Korea
Prior art keywords
group
formula
substituted
lower alkyl
ring
Prior art date
Application number
KR1019930701814A
Other languages
English (en)
Other versions
KR100252428B1 (ko
Inventor
사찌오 모리
쇼조 다께찌
시로 기다
다꾸지 미즈이
데루히사 이찌하시
Original Assignee
시오노 요시히꼬
시오노기 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시오노 요시히꼬, 시오노기 세이야꾸 가부시끼가이샤 filed Critical 시오노 요시히꼬
Publication of KR930703236A publication Critical patent/KR930703236A/ko
Application granted granted Critical
Publication of KR100252428B1 publication Critical patent/KR100252428B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/22—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one naphthalene or hydrogenated naphthalene ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)

Abstract

본 발명은 피내에 있는 총 콜레스테롤 중 동맥경화의 위험인자로 고려되는 LDL 및 VLDL 콜레스테롤에 대한 저항 작용이 강하고, 각각 LDL에 대해 우수한 항산화 작용을 갖는 항지혈증제를 제공한다.
또한, 본 발명은 하기 일반식(Ⅰ)로 표시되는 화합물 및 그의 약학적으로 허용되는 염을 제공하는데 있다.
상기 식에서, R1은 치환되거나 비치환된 저급 알킬기, 사이클로알킬기, 사이클로알킬 저급 알킬기, 아릴기 또는 아르알킬기 이고, R2는 식; -COOR′표시되는 기 저급 아킬기 또는 할로겐화 저급 알킬기이거나, 또는 R1및 R2는 인접한 카보닐기와 함께 식으로 표시되는 사이클로헥사논환을 형성하고 , R3은 치환되거나 비치환된 폐닐기이고, A환은 치환되거나 비치환된 벤젠환된, 또는 S 또는 0 중의 어느 하나를 함유하고 또한 치환되거나 비치환된 복소환을 나타낸다.

Description

리그난 유사체. 이의 제조방법 및 이를 함유한 항지혈증제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 일반식(1)로 표시되는 화합물 및 그의 약학적으로 허용되는 염;
    상기식에서, R1은 치환되거나 비치환된 저급 알킬기, 사이클로알킬기, 사이클로알킬 저급 알킬기, 아릴기 또는 아르알킬기이고, R2는 식; -COOR′(여기서, R′는 치환되거나 비치환된 저급 알킬기 또는 아르알킬기이다)로 표시되는 기, 저급 알킬기 또는 할로겐화 저급 알킬기이거나, 또는 R1및 R2는 카보닐기와 함께 식으로 표시되는 사이클로헥사논환을 형성하고, R3은 치환되거나 비치환된 페닐기이고, A환은 치환되거나 비치환돈 벤젠환, 또는 S 또는 0 중의 어느 하나를 함유하고 또한 치환되거나 비치환된 복소환을 나타낸다.
  2. 제1항 또는 제2항에 있어서, A환이 3개의 메톡시기로 치환된 벤젠환이고, R3이 2개의 메톡시기로 치환된 페닐기인 화합물.
  3. 내용 없음.
  4. 하기 일반식 (Ⅱ)로 표시되는 화합물에 하기 일반식(Ⅲ)으로 표시되는 화합물을 부가 반응시킴을 특징으로 하는 일반식(Ⅰ)의 화합물의 제조 방법.
    상기식에서 A환, R3및 R1은 상기 정의한 바와 같고, R2는 식:-COOR′(여기서, R′는 치환되거나 비치환된 저급 알킬기 또는 아르알킬기이다)로 표시되는 기이다.
  5. 하기 일반식(Ⅳ)로 표시되는 화합물에 하기 일반식(Ⅴ)로 표시되는 화합물을 치환 반응시킴을 특징으로 하는 일반식(1)의 화합물의 제조방법.
    상기식에서 A환, R1및 R3는 상기 정의한 바와 같고, R2는 식:-COOR′(여기서, R′는 치환되거나 비치환된 저급 알킬기 또는 아르알킬기이다)로 표시되는 기이고 M은 리튬원자 또는 마그네슘 원자-할로겐원자로 이루어진 기를 나타낸다.
  6. 제1항 내지 제3항 중 어느 한 항에 기재된 화합물을 약학적 활성 성분으로서 함유한 제6항에 기재된 항지혈증제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930701814A 1991-10-17 1992-10-15 리그난유사체,이의제조방법및이를함유한항지혈증제 KR100252428B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP91-298119 1991-10-17
JP29811991 1991-10-17
PCT/JP1992/001342 WO1993008155A1 (en) 1991-10-17 1992-10-15 Lignan analog, production thereof, and hypolipidemic drug

Publications (2)

Publication Number Publication Date
KR930703236A true KR930703236A (ko) 1993-11-29
KR100252428B1 KR100252428B1 (ko) 2000-04-15

Family

ID=17855421

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930701814A KR100252428B1 (ko) 1991-10-17 1992-10-15 리그난유사체,이의제조방법및이를함유한항지혈증제

Country Status (12)

Country Link
US (4) US5420333A (ko)
EP (2) EP0701991B1 (ko)
JP (1) JP2839805B2 (ko)
KR (1) KR100252428B1 (ko)
AT (2) ATE175954T1 (ko)
DE (2) DE69211994T2 (ko)
DK (2) DK0597107T3 (ko)
ES (2) ES2129733T3 (ko)
GR (1) GR3020461T3 (ko)
HU (1) HU211296A9 (ko)
TW (1) TW209215B (ko)
WO (1) WO1993008155A1 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488134A (en) * 1993-04-16 1996-01-30 Shionogi & Co., Ltd. Preparation of compounds of lignan series
FR2707980B1 (fr) * 1993-07-20 1995-09-01 Adir Nouveaux cyclohept[b]indoles et cyclooct[b]indoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
WO1995035291A1 (fr) * 1994-06-22 1995-12-28 Shionogi & Co., Ltd. Procede de production d'un compose de phtalide
ID18046A (id) * 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
CA2350213A1 (en) * 1998-11-12 2000-05-18 Alteon, Inc. Glucose and lipid lowering compounds
KR100352269B1 (ko) * 1999-10-08 2002-09-12 한국생명공학연구원 저밀도 지질 단백질에 대해 항산화 활성을 갖는 리그난계 화합물
FR2800738B1 (fr) 1999-11-04 2002-02-08 Corning Sa Naphtopyranes ayant un substituant perfluoroalkyle en position 5, preparation et compositions et matrices (co)polymeres les renfermant
US6770024B1 (en) * 2000-03-28 2004-08-03 Stony Brook Surgical Innovations, Inc. Implantable counterpulsation cardiac assist device
TWI241195B (en) * 2000-04-10 2005-10-11 Shionogi & Co Preventive agent for bile acidic diarrhea
CN1466465A (zh) * 2000-08-01 2004-01-07 ��Ұ����ҩ��ʽ���� 肥胖或脂肪肝的预防或治疗药物
AU2003271115A1 (en) * 2002-10-08 2004-05-04 Shionogi And Co., Ltd. Process for producing enone ester
US7152611B2 (en) * 2002-12-30 2006-12-26 International Tape Partners, Llc Coated multifilament dental devices overcoated with imbedded particulate
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
EP2771003B1 (en) 2011-10-28 2017-04-19 Lumena Pharmaceuticals LLC Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP2770990A4 (en) 2011-10-28 2015-03-11 Lumena Pharmaceuticals Inc Gallic acid refluxing agent for the treatment of hypertension and chronic liver disease
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
WO2014144485A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
BR112021015815A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para tratar colestase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771072A (en) * 1985-01-10 1988-09-13 Tanabe Seiyaku Co., Ltd. Alkoxynaphthalene derivatives
JPS6310746A (ja) * 1986-07-01 1988-01-18 Tanabe Seiyaku Co Ltd ナフタレン誘導体
JPH0372422A (ja) * 1989-05-16 1991-03-27 Tanabe Seiyaku Co Ltd 抗脂血剤

Also Published As

Publication number Publication date
DE69228262D1 (de) 1999-03-04
US5449814A (en) 1995-09-12
DE69211994D1 (de) 1996-08-08
US5420333A (en) 1995-05-30
KR100252428B1 (ko) 2000-04-15
ES2129733T3 (es) 1999-06-16
JPH05310634A (ja) 1993-11-22
EP0701991B1 (en) 1999-01-20
TW209215B (ko) 1993-07-11
WO1993008155A1 (en) 1993-04-29
ATE175954T1 (de) 1999-02-15
EP0701991A1 (en) 1996-03-20
EP0597107B1 (en) 1996-07-03
US5731455A (en) 1998-03-24
US5502216A (en) 1996-03-26
HU211296A9 (en) 1995-11-28
DK0701991T3 (da) 1999-09-13
GR3020461T3 (en) 1996-10-31
DK0597107T3 (da) 1996-07-29
ATE139990T1 (de) 1996-07-15
DE69211994T2 (de) 1997-02-20
EP0597107A4 (en) 1994-02-03
EP0597107A1 (en) 1994-05-18
JP2839805B2 (ja) 1998-12-16
ES2091488T3 (es) 1996-11-01

Similar Documents

Publication Publication Date Title
KR930703236A (ko) 리그난 유사체. 이의 제조방법 및 이를 함유한 항지혈증제
DE10199003I2 (ko)
GB8919417D0 (en) Novel compounds
AU6128590A (en) Novel compounds
PL307087A1 (en) Novel heterocyclic compounds for use as pharmaceuticals
KR910002800A (ko) 4-아실록시퀴놀린 유도체와 이를 함유하는 살충 또는 살비조성물
KR930016436A (ko) 4, 13-디옥사바이사이클로[8.2.1]트리데세논유도체와 그의 제조방법, 그의 제조를 위한 중간체 및 이화합물이 함유된 약학조성물
KR890011829A (ko) 디우레아 유도체 및 이의 제조방법
KR900003179A (ko) 벤조디아제핀 화합물 및 약제로서의 이의 용도
EG19557A (en) A process for the preparation of pharmaceutical preparation
IL86741A0 (en) Thiophene derivatives,their preparation and pharmaceutical compositions containing them
PT88462A (pt) Process for the preparation of macrolide compounds and of compositions containing them
KR920002613A (ko) 이환성 함유 황화합물
KR890005068A (ko) 에탄온 옥심
KR890009896A (ko) 디옥사조신 유도체, 그의 제법 및 그를 함유하는 조성물
KR910014369A (ko) 이미다졸릴 프로필 구아니딘 유도체와 그 제조방법 및 이를 함유하는 약학적 조성물
KR830005157A (ko) 페녹시-아미노프로판올 유도체의 제조방법
KR880001631A (ko) 퀴놀린 유도체의 제조 방법
KR930700501A (ko) 신규 설포닐 화합물
KR830010102A (ko) 항세균 활성을 갖는 신규의 벤조[b] 티오펜 벤조[b]푸란, 티오크로만 및 크로만의 제조방법
KR940002252A (ko) 우수한 항균작용을 갖는 신규한 피리돈 카르복실산 유도체 및 그의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060110

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee